Discovery Labs preparing Surfaxin response to FDA

After seeing its stock price slide 10 percent at the beginning of the week after the FDA requested more information on its lung treatment Surfaxin, Discovery Labs announced today that it will respond to the agency's request in October. But executives at the company emphasized that the dozen points the FDA wants clarified deal with chemistry and manufacturing issues, not the results of the clinical trials used to obtain an "approvable" letter.

- read this AP story for more

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.